5 results about "Hedgehog signaling pathway" patented technology

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.

The present application relates to the application of imperatorin in the preparation of a drug for inhibiting the Hedgehog signal pathway, and discloses that imperatorin can inhibit the Hedgehog signal pathway activated by Shh, inhibit the Hedgehog signal pathway activity activated by SMO overexpression, and inhibit the Hedgehog signal pathway activity activated by SMO drug-resistant mutation, and can obviously inhibit the growth of tumors in vivo caused by abnormal activation of the Hedgehog, and in particular, it is disclosed that imperatorin can inhibit the Hedgehog signal pathway activity activated by SMO drug-resistant mutation, which provides a new strategy for treating tumors caused by abnormal activation of the Hedgehog, and expands the application field of imperatorin.

The present application relates to a kind of novel Hedgehog signal pathway inhibitor and preparation method thereof, the Hedgehog signal pathway inhibitor has the structure shown in formula (I).The Hedgehog signal pathway inhibitor of the present application can effectively inhibit SMO receptor activity, and block SHH signal pathway. With good effect of blocking the seizure caused by excessive or super-synchronous neuron discharge in brain. As epilepsy treatment candidate drug has good application prospect.

The application provides application of chamaecyparis funebris polysaccharide in preparation of a medicine for preventing and / or treating pulmonary fibrosis, and belongs to the technical field of medicines.The application finds that chamaecyparis funebris polysaccharide can effectively prevent and / or treat pulmonary fibrosis, and can effectively reduce lung injury and inhibit lung inflammation; chamaecyparis funebris polysaccharide inhibits fibrosis and migration of human embryo lung fibroblasts induced by recombinant human transforming growth factor, improves lung function injury and pulmonary fibrosis of a bleomycin-induced pulmonary fibrosis mouse, inhibits inflammatory cell infiltration of bronchial alveoli and expression of NOD-like receptor family pyridine domain-containing protein 3 (NLRP3) in lung tissue of the pulmonary fibrosis mouse, and further inhibits lung inflammation; chamaecyparis funebris polysaccharide can also inhibit the Hedgehog signal pathway in vitro and in vivo, and the improvement of lung function of the bleomycin-induced pulmonary fibrosis mouse and the treatment of pulmonary fibrosis by chamaecyparis funebris polysaccharide are further enhanced when assisted by a Hedgehog pathway inhibitor.